# Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

> **NCT01465334** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- CLL
- SLL

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** High-Dose Methylprednisolone
- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT01465334
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2014-11
- **Final completion:** 2017-01
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Terminated early due to change in practice.
- **Last updated:** 2023-08-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465334, "Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01465334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*